NEXT GENERATION ADC
ADC has emerged as an important modality to deliver drugs with improved precision, and will remain an important modality against cancer. InxMed has developed ADC to address with aims of stronger, more potent ADC to overcome emerging resistance and companion biomarker test sparing. We firmly believe that we can develop ADCs for tumor selective across with relatively broad spectrum but also relatively normal tissue sparing.
Our next generation ADCs will be entering IND enabling study in Q3 2024 and will address the key unmet medical need.
We invent personalized medicines with global impact, and turn innovation in China to life saving therapies for the world
QUICK LINKS
CONTACT US
Tel: +86 25-58251030
Email: office@inxmed.com
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing
MESSAGE
Follow Us:
CopyRight © 2022 InxMed All Rights Reserved.